Grand Pharmaceutical Group Ltd
HKEX:512
Grand Pharmaceutical Group Ltd
EPS (Diluted)
Grand Pharmaceutical Group Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
EPS (Diluted)
HK$0
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
EPS (Diluted)
¥1
|
CAGR 3-Years
39%
|
CAGR 5-Years
30%
|
CAGR 10-Years
16%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-37%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
C
|
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
-24%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
EPS (Diluted)
HK$0
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Grand Pharmaceutical Group Ltd
Glance View
Grand Pharmaceutical Group Ltd. stands as a significant player in the pharmaceutical industry, strategically positioned in the bustling hub of the Asia-Pacific region. Founded with a vision to harness scientific innovation for healing, the company has diligently expanded its reach and capabilities over the years. Grand Pharma is meticulously structured around three core segments: Medicine and Healthcare, Biopharmaceutical Manufacturing, and Medical Devices. In the Medicine and Healthcare segment, it advances an extensive portfolio of both proprietary and generic drugs. This segment alone accounts for a substantial portion of its revenue, capitalizing on its adeptness in research and development to maintain a robust pipeline of products. By continuously innovating and seeking to meet unmet medical needs, Grand Pharma sustains its competitive edge in the market. Their Biopharmaceutical Manufacturing segment shines brightly as a beacon of future growth, showcasing their commitment to biotechnology. Here, Grand Pharmaceutical leverages cutting-edge biotechnologies to develop therapies targeting a range of complex diseases. This segment is noted for its high-margin potential, driven by the increasing global demand for biologics. Furthermore, their Medical Devices segment complements the pharmaceutical operations by delivering state-of-the-art products in areas such as cardiovascular health and surgical equipment. By maintaining a balanced and diversified portfolio across these business areas, Grand Pharmaceutical effectively mitigates risks and capitalizes on emerging trends in global healthcare markets. Through astute strategic planning and an unwavering commitment to quality and innovation, the company fortifies its position as a leader in the field, continually reinvesting its profits to further enhance its offerings and broaden its impact.
See Also
What is Grand Pharmaceutical Group Ltd's EPS (Diluted)?
EPS (Diluted)
0.7
HKD
Based on the financial report for Dec 31, 2024, Grand Pharmaceutical Group Ltd's EPS (Diluted) amounts to 0.7 HKD.
What is Grand Pharmaceutical Group Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
23%
Over the last year, the EPS (Diluted) growth was 30%. The average annual EPS (Diluted) growth rates for Grand Pharmaceutical Group Ltd have been 1% over the past three years , 16% over the past five years , and 23% over the past ten years .
You don't have any saved screeners yet